Interpace Diagnostics High Margin Molecular Diagnostic Tests & Pathology Services

Interpace Diagnostics (NASDAQ: IDXG) provides clinically useful molecular diagnostic tests and pathology services for evaluating the risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. With three commercial molecular tests currently on the market, IDXG’s goal is to provide personalized medicine though molecular diagnostics and innovation to advance patient care and reduce the cost of healthcare based on rigorous science.

You might be interested in